Arkolith/Insider Trading/EVLO/Form 4/A

Gill Simba

President & CEO, DirectorEvelo Biosciences, Inc. (EVLO) · full profile →Form 4/A · filed May 10, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 7, 2023Option exercise(M)23K—$0352K

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001694665-23-000046) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML